Edition:
United States

Neuren Pharmaceuticals Ltd (NEU.AX)

NEU.AX on Australia Stock Exchange

0.08AUD
24 Mar 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.08
Open
$0.08
Day's High
$0.08
Day's Low
$0.08
Volume
3,768,428
Avg. Vol
1,770,333
52-wk High
$0.12
52-wk Low
$0.04

NEU.AX

Chart for NEU.AX

About

Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company engaged in developing drugs for neurological disorders. The Company develops therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $141.56
Shares Outstanding(Mil.): 1,791.93
Dividend: --
Yield (%): --

Financials

  NEU.AX Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -0.01 -- --
ROI: -129.29 -2.56 13.01
ROE: -129.29 5.14 14.16

BRIEF-Neuren's Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric rett syndrome

* Neuren's Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric rett syndrome Source text for Eikon:

Mar 24 2017

BRIEF-Neuren Pharmaceuticals requests trading halt

* Requests trading halt pending announcement regarding Neuren's phase 2 clinical trial of Trofinetide in Rett Syndrome Source text for Eikon: Further company coverage:

Mar 17 2017

BRIEF-Neuren Pharmaceuticals completes Phase 2 trial in Pediatric Rett Syndrome

* Neuren completes phase 2 trial in Pediatric Rett Syndrome Source text for Eikon: Further company coverage:

Jan 29 2017

More From Around the Web

Earnings vs. Estimates